Taysha Gene Therapies, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
Taysha Gene Therapies, Inc. (TSHA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $1.41 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-19
- Taysha Gene Therapies, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2025 was $1.41M, a 30.82% decline from fiscal 2024.
- Taysha Gene Therapies, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was $2.03M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2025-12-31 | $1.41M 10-K · filed 2026-03-19 |
| 2024-12-31 | $2.03M 10-K · filed 2026-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |